Fludarabine–Mitoxantrone–Rituximab regimen in untreated indolent non‐follicular non‐Hodgkin's lymphoma: experience on 143 patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|278-0232|3|141-146

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.278-0232, Iss.3, 2015-09, pp. : 141-146

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fludarabine–Mitoxantrone–Rituximab regimen in untreated indolent non‐follicular non‐Hodgkin's lymphoma: experience on 143 patients

By  

Hematological Oncology (Electronic), Vol. 33, Iss. 3, 2015-09 ,pp. : 141-146

John Wiley & Sons Inc

Access to resources Recommend Favorite

Fludarabine: A Review of its Use in Non-Hodgkin's Lymphoma

By Anderson Vanessa R.   Perry Caroline M.  

Drugs, Vol. 67, Iss. 11, 2007-01 ,pp. : 1633-1655

Adis International

Access to resources Recommend Favorite

Bendamustine: A Review of its Use in the Management of Chronic Lymphocytic Leukaemia, Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma and Multiple Myeloma

By Hoy Sheridan M.  

Drugs, Vol. 72, Iss. 14, 2012-10 ,pp. : 1929-1950

Adis International

Access to resources Recommend Favorite

Infliximab: Non-Hodgkin's follicular lymphoma: case report

By  

Reactions Weekly, Vol. 1, Iss. 1350, 2011-01 ,pp. : 28-28

Adis International

Access to resources Recommend Favorite

Economic Burden of Follicular Non-Hodgkin's Lymphoma

By Foster Talia  

PharmacoEconomics, Vol. 27, Iss. 8, 2009-08 ,pp. : 657-679

Adis International

Access to resources Recommend Favorite